The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
During a roughly five-year span, CVS Health, Cigna, and UnitedHealth benefited the most from increasing prices for generic drugs that treated illnesses such as HIV and cancer. Some of the price hikes ...
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
Margin expansion at Express Scripts, Caremark and Optum Rx increased by $336 million between 2017 and 2021, officials say.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback